SENZUMODERN REBIRTHMy account TB-500
Also known as N-acetylated LKKTETQ · thymosin beta-4 fragment
FDA found no identified human exposure data for drug products containing the TB-500 fragment. Human studies of full-length thymosin beta-4 or ophthalmic RGN-259 cannot be presented as evidence for TB-500.
- Evidence maturity
- Early signal
- Regulatory status
- Not FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
This profile does not recommend a compound, dose, supplier, or treatment plan. Discuss personal decisions with a qualified clinician who knows your history.
Summary
An unapproved seven-amino-acid fragment often confused with full-length thymosin beta-4.
What is TB-500 being studied for?
Cell migration and wound-repair research
How is it thought to work?
A synthetic acetylated fragment corresponding to residues 17 through 23 of thymosin beta-4; proposed repair mechanisms are not established in humans for this fragment.
Recorded outcomes
3 graded outcomes and 3 sources for TB-500.
The graded outcome table, how each grade was decided, the regulatory detail, and every source with its link and identifier open with a free account. No payment details required.
Update history
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.